Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...

Researchers discovered that a tiny structural feature of the enzyme GPX4 helps keep neurons safe. A rare mutation removes this protection, allowing harmful molecules to damage cell membranes and ...

Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...

Research links variations in the gene GRIN2A to a higher risk of developing schizophrenia and other forms of mental illness. The GRIN2A gene regulates communication between neurons by producing the ...

This time, that direction was artificial intelligence. Warshel's first AI-based effort focused on trying to predict how mutations in enzymes alter their activity. In the case of viruses like HIV, ...

A newly developed AI can predict which diseases specific genetic mutations are likely to cause, not just whether they are harmful. The breakthrough could speed up diagnoses and open new paths for ...

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...

Stage 1 myelofibrosis is a chronic condition with minimal symptoms, requiring early diagnosis for effective monitoring and intervention. Treatment options include active surveillance, JAK inhibitors, ...

A sperm donor who unknowingly harboured a genetic mutation that dramatically raises the risk of cancer has fathered at least 197 children across Europe, a major investigation has revealed. Some ...

Company to present at 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15Label expansion submissions for BESREMi® (ropeginterferon alfa-2b-njft) filed with FDABURLINGTON, ...